View Older Stories View More Recent Stories

Oct 11, 2017 08:41AM Oxitec do Brasil Receives Prestigious Award for Innovation and Impact
Oct 4, 2017 01:00PM Transfer of Regulatory Jurisdiction for Oxitec's Self-limiting Friendly™ Aedes in the United States
Oct 2, 2017 04:30PM Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa
Sep 26, 2017 08:03AM Fibrocell Science (FCSC) Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for RDEB
Sep 26, 2017 08:00AM Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Sep 19, 2017 11:00AM Oxitec to Build State-of-the-Art Mosquito Egg Production Unit
Sep 5, 2017 06:39AM Intrexon (XON) Oxitec's Begins Field Trials of Genetically Engineered Diamondback Moth
Sep 5, 2017 03:00AM Oxitec's Innovative Solution to Tackle Growing Diamondback Moth Pest Issue Begins Field Trials
Aug 31, 2017 04:01PM Intrexon to Participate in Upcoming Investor Conferences
Aug 9, 2017 04:05PM Intrexon Announces Second Quarter and First Half 2017 Financial Results
Aug 9, 2017 08:00AM Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights
Aug 2, 2017 08:00AM Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th
Aug 2, 2017 08:00AM Fibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights
Jul 11, 2017 10:00AM Oxitec Launching Friendly™ Aedes Project in Juiz de Fora, Brazil
Jul 6, 2017 08:30AM Oxitec's Friendly™ Aedes Mosquito Receives Positive Evaluation for European Standard in relation to Human Health and the Environment
Jun 29, 2017 03:30PM Intrexon Appoints Helen Sabzevari, Ph.D., Senior Vice President, Human Therapeutics and Head of Research and Development of Precigen
Jun 16, 2017 09:15AM Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition
Jun 13, 2017 07:00AM Intrexon and Johnson Matthey Collaborate on Fermentative Production of Peptide-based Active Pharmaceutical Ingredients
Jun 12, 2017 08:01AM Fibrocell Science (FCSC) Announces Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma
Jun 12, 2017 08:00AM Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma
Jun 8, 2017 08:07AM Fibrocell Science (FCSC) Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for RDEB
Jun 8, 2017 08:00AM Fibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
May 31, 2017 08:00AM Intrexon's Head of Environment Sector Joins Brazil Investment Forum to Discuss Importance of Vector Control and Economic Impact of Vector-borne Diseases
May 24, 2017 08:00AM Intrexon to Present at Upcoming Investor and Industry Conferences
May 18, 2017 04:02PM Intrexon (XON) Confirms Dr. Mark Carnegie-Briwn as CEO of Oxitec
May 18, 2017 04:01PM Intrexon Appoints Dr. Mark Carnegie-Brown as CEO of Oxitec
May 17, 2017 08:00AM Fibrocell to Present at Inaugural Cell & Gene Exchange 2017
May 15, 2017 08:00AM Intrexon to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
May 10, 2017 04:05PM Intrexon Announces First Quarter 2017 Financial Results
May 10, 2017 08:00AM Intrexon and Darling to Build Commercial-scale Production of Insect-Based Advanced Feed Ingredients
May 10, 2017 08:00AM Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights
May 9, 2017 09:14AM Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
May 9, 2017 08:00AM Huvepharma to Utilize Intrexon's Proprietary Fungal Expression Platform to Produce Key Animal Feed Enzyme
May 8, 2017 08:14AM Fibrocell Science (FCSC) Announces DSMB Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of RDEB
May 8, 2017 08:00AM Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
May 3, 2017 08:00AM Intrexon to Announce First Quarter 2017 Financial Results on May 10th
May 3, 2017 08:00AM Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
Apr 27, 2017 08:00AM Intrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors
Apr 13, 2017 08:00AM Fibrocell to Present at 7th Annual World Orphan Drug Congress USA 2017 and 5th Annual Cell & Gene Therapy Investor Day
Apr 10, 2017 07:00AM The Municipality of Santiago de Cali, Colombia, and Oxitec Ltd. Announce Memorandum to Deploy Friendly™ Aedes
Apr 3, 2017 07:16AM Ziopharm Oncology (ZIOP), Merck (MRK) & Intrexon (XON) Announce Development Update on CAR-T Therapy for Cancer
Apr 3, 2017 07:00AM Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Platform Empowered by Membrane-Bound IL-15 Under RheoSwitch Therapeutic System® Control
Mar 30, 2017 07:09AM Intrexon (XON) Announces Oxitec's Friendly Aedes Achieves 81% Suppression of Wild Aedes aegypti in CECAP/Eldorado, Piracicaba, in Second Year of Project
Mar 30, 2017 07:00AM Oxitec's Friendly™ Aedes Achieves 81% Suppression of Wild Aedes aegypti in CECAP/Eldorado, Piracicaba, in Second Year of Project
Mar 17, 2017 07:00AM Jorge Espanha Appointed General Manager of Oxitec do Brasil
Mar 10, 2017 04:17PM Intrexon (XON) Forms Precigen Subsidiary; Accelerates Strategic Review of Structural Options Related to Health Assets
Mar 10, 2017 04:15PM Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health Assets
Mar 9, 2017 08:00AM Fibrocell Reports 2016 Financial Results and Recent Operational Highlights
Mar 7, 2017 05:15PM Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial Results and Recent Operational Highlights
Mar 7, 2017 04:54PM Fibrocell Announces Convertible Preferred Stock Financing for $8.0 Million
View More Recent Stories View Older Stories